U.S. market Closed. Opens in 14 hours 8 minutes

AVBP | ArriVent BioPharma, Inc. Common Stock Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-31
RevenueN/AN/AN/A
Cost of RevenueN/AN/AN/A
Gross ProfitN/AN/AN/A
Operating Expenses74.59M36.91M8.70M
Selling, General & Admin9.71M6.47M2.26M
Research & Development64.88M30.43M6.43M
Other Operating ExpensesN/AN/AN/A
Operating Income-74.59M-36.91M-8.70M
Other Expenses / Income5.26MN/A-60.11M
Before Tax Income-69.33M-36.91M-51.61M
Income Tax ExpensesN/A-36.91M-11.59M
Net Income-69.33M-36.91M-51.61M
Interest ExpensesN/AN/AN/A
Basic Shares Outstanding31.96M33.49M33.49M
Diluted Shares Outstanding31.96M33.49M33.49M
EBITDA-74.59M-36.91M-51.61M
EBITDA Margin0.00%0.00%0.00%
EBIT-69.33M-73.81M-63.20M
EBIT Margin0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙